Information:
In this position, we offer insights into the aspects of discovery and characterization of biotherapeutics in a dynamic team within the biotech company. You will be working on the design, development and functional testing of assays (e.g. SPR, ELISA) for the characterization of binding properties of innovative antibody-based therapeutics.
Your Responsibilities:
- Screen antibody candidates by High-throughput SPR
- Determine binding affinities and kinetics (e.g. SPR), or potency and efficacy (e.g. ELISA) of antibodies, antibody fragments and multi-specific antibody-based proteins to their targets
- Develop assays to measure binding affinity, kinetics, potency and efficacy (SPR and ELISA)
- Maintain accurate written records of research activities including regularly updating electronic data and reporting data in written and oral presentations at different levels
We are looking for a highly motivated individual who is keen on developing and learning new techniques, and who has a very accurate working style.
Ideal candidates will have:
- Apprenticeship as laboratory technician, and/or BSc/MSc, in biology or related fields
- High motivation in learning new techniques and improving scientific skills
- High accuracy and team-oriented working style paired with a high sense of quality and the ability to work independently on diverse challenges
- Hands-on experience in handling analytical protein samples or conducting SPR-based kinetic measurements will be considered as beneficial
- Experience with the characterization of proteins in ELISA is beneficial
- Good computer (Windows, MS Office) and communication skills
- Sound oral and written English
What we offer:
- A diverse field of activities in a dynamic team with an inspiring, entrepreneurial atmosphere
- Flat hierarchies and short decision-making paths
- Several fun team events throughout the year
- A workplace near the city of Zurich, overlooking the lake
About us:
Numab Therapeutics AG is an expanding, Swiss biotech company based in Horgen, canton of Zürich. The company is focused on the discovery and development of innovative, antibody fragment-based therapeutics especially in the area of inflammation and immuno-oncology. With our breakthrough antibody-discovery and multi-specifics engineering platform, we engage in proprietary projects as well as collaborative research on behalf of partners in the pharmaceutical industry.